Whilst there was only a limited pool of relatively small trials and a number of different compounds , we found that collectively , both AChEIs ( donepezil and rivastigmine ) and stimulants ( methylpheni date , modafinil , l‐amphetamine sulfate and lisdexamfetamine dimesylate ) offered no significant benefits over placebo on measures of processing speed , working memory , verbal fluency , verbal memory , visuospatial memory or executive functioning
HighlightsCognitive deficits are present in up to 70 % of people with multiple sclerosis (MS).There are no approved treatments for these difficulties .
We examined whether adjunctive pharmacotherapies can improve cognition in MS.Acetylcholinesterase inhibitors offered no significant benefits over placebo .
Stimulant‐based medications offered no significant benefits over placebo .
& NA ; We sought to examine the effectiveness of acetylcholinesterase inhibitors ( AChEIs ) and stimulant‐based medications for improving cognitive performance in patients with multiple sclerosis ( MS ) .
Effects of exercise on fitness and cognition in progressive MS: a randomized, controlled pilot trial
Background : Exercise may have beneficial effects on both well-being and walking ability in multiple sclerosis ( MS ) .  Exercise is shown to be neuroprotective in rodents and may also enhance cognitive function in humans . It may , therefore , be particularly useful for MS patients with pronounced neurodegeneration . Objective : To investigate the potential of st and ardized exercise as a therapeutic intervention for progressive MS , in a r and omized-controlled pilot trial . Methods : Patients with progressive MS and moderate disability ( Exp and ed Disability Status Scale ( EDSS ) of 4–6 ) were r and omized to one of three exercise interventions ( arm ergometry , rowing , bicycle ergometry ) for 8–10 weeks or a waitlist control group . We analyzed the drop-out rate as a measure of feasibility . The primary endpoint of the study was aerobic fitness . Secondary endpoints were walking ability , cognitive function as measured by a neuropsychological test battery , depression and fatigue . Results : A total of 42 patients completed the trial ( 10.6 % drop-out rate ) . Significant improvements were seen in aerobic fitness . In addition , exercise improved walking ability , depressive symptoms , fatigue and several domains of cognitive function . Conclusion : This study indicated that aerobic training is feasible and could be beneficial for patients with progressive MS . Larger exercise studies are needed to confirm the effect on cognition . Trial Registration : IS RCT N ( trial number 76467492 ) http://is rct
Whilst there was only a limited pool of relatively small trials and a number of different compounds , we found that collectively , both AChEIs ( donepezil and rivastigmine ) and stimulants ( methylpheni date , modafinil , l‐amphetamine sulfate and lisdexamfetamine dimesylate ) offered no significant benefits over placebo on measures of processing speed , working memory , verbal fluency , verbal memory , visuospatial memory or executive functioning
HighlightsCognitive deficits are present in up to 70 % of people with multiple sclerosis (MS).There are no approved treatments for these difficulties .
We examined whether adjunctive pharmacotherapies can improve cognition in MS.Acetylcholinesterase inhibitors offered no significant benefits over placebo .
Stimulant‐based medications offered no significant benefits over placebo .
& NA ; We sought to examine the effectiveness of acetylcholinesterase inhibitors ( AChEIs ) and stimulant‐based medications for improving cognitive performance in patients with multiple sclerosis ( MS ) .